Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527767) titled 'Secondary Use of PARALLEL-HF Data' on April 7.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)

Recruitment Status: Not recruiting

Date of First Enrollment: July 27, 2022

Target Sample Size: 236

Countries of Recruitment: Japan

To know more, visit https://clinicaltrials.gov/study/NCT07527767

Disclaimer: Curated by HT Syndication....